AU2018306329B8 - Methods of protecting vascular integrity induced by targeted radiation therapy - Google Patents

Methods of protecting vascular integrity induced by targeted radiation therapy Download PDF

Info

Publication number
AU2018306329B8
AU2018306329B8 AU2018306329A AU2018306329A AU2018306329B8 AU 2018306329 B8 AU2018306329 B8 AU 2018306329B8 AU 2018306329 A AU2018306329 A AU 2018306329A AU 2018306329 A AU2018306329 A AU 2018306329A AU 2018306329 B8 AU2018306329 B8 AU 2018306329B8
Authority
AU
Australia
Prior art keywords
subject
minutes
radiation therapy
tpo mimetic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018306329A
Other languages
English (en)
Other versions
AU2018306329A8 (en
AU2018306329B2 (en
AU2018306329A1 (en
Inventor
Gary Eichenbaum
Alfred Tonelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2018306329A1 publication Critical patent/AU2018306329A1/en
Publication of AU2018306329B2 publication Critical patent/AU2018306329B2/en
Application granted granted Critical
Publication of AU2018306329A8 publication Critical patent/AU2018306329A8/en
Publication of AU2018306329B8 publication Critical patent/AU2018306329B8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
AU2018306329A 2017-07-26 2018-07-26 Methods of protecting vascular integrity induced by targeted radiation therapy Ceased AU2018306329B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762537049P 2017-07-26 2017-07-26
US62/537,049 2017-07-26
PCT/US2018/043821 WO2019023418A1 (en) 2017-07-26 2018-07-26 METHODS FOR PROTECTING VASCULAR INTEGRITY INDUCED BY TARGETED RADIOTHERAPY

Publications (4)

Publication Number Publication Date
AU2018306329A1 AU2018306329A1 (en) 2020-02-13
AU2018306329B2 AU2018306329B2 (en) 2024-09-19
AU2018306329A8 AU2018306329A8 (en) 2025-02-20
AU2018306329B8 true AU2018306329B8 (en) 2025-02-20

Family

ID=63165522

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018306329A Ceased AU2018306329B8 (en) 2017-07-26 2018-07-26 Methods of protecting vascular integrity induced by targeted radiation therapy

Country Status (11)

Country Link
US (1) US12251424B2 (https=)
EP (1) EP3658191A1 (https=)
JP (1) JP7481252B2 (https=)
KR (1) KR102688415B1 (https=)
CN (1) CN111432845B (https=)
AU (1) AU2018306329B8 (https=)
BR (1) BR112020001367A2 (https=)
CA (1) CA3070442A1 (https=)
IL (1) IL272213A (https=)
PH (1) PH12020500166A1 (https=)
WO (1) WO2019023418A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008943A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
CN119654158A (zh) * 2022-05-20 2025-03-18 詹森药业有限公司 用于减轻与暴露于辐射和/或辐射或拟辐射治疗相关的肺损伤的方法
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
WO2025002113A1 (zh) * 2023-06-26 2025-01-02 上海济煜医药科技有限公司 一种人血小板生成素受体激动剂的融合蛋白

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040750A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
WO1998025965A2 (en) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides and compounds that bind to the thrombopoietin receptor
WO2005023834A2 (en) * 2003-08-28 2005-03-17 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to thrombopoietin receptors
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
US20080119384A1 (en) * 2004-08-16 2008-05-22 Yurkow Edward J Use of TPO peptide compounds and pharmaceutical compostions in the treatment of anemia
JP2012518408A (ja) * 2009-02-24 2012-08-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
DK1984014T3 (da) 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
CN100391474C (zh) * 2006-06-13 2008-06-04 卢建军 用于治疗血小板减少的注射用药物
CA2670345A1 (en) 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
US8383124B2 (en) 2008-03-12 2013-02-26 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
ES2729622T3 (es) 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
JP2012250880A (ja) 2011-06-03 2012-12-20 Semiconductor Energy Lab Co Ltd グラフェン、蓄電装置および電気機器
US20140047572A1 (en) 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US20140051631A1 (en) 2012-08-17 2014-02-20 Francoise Porteu Pharmaceutical composition comprising tpo or an agonist of the tpo receptor
JP6150374B2 (ja) 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
WO2020154637A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
MX2021008943A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040750A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
WO1998025965A2 (en) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides and compounds that bind to the thrombopoietin receptor
WO2005023834A2 (en) * 2003-08-28 2005-03-17 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to thrombopoietin receptors
US20080119384A1 (en) * 2004-08-16 2008-05-22 Yurkow Edward J Use of TPO peptide compounds and pharmaceutical compostions in the treatment of anemia
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
JP2012518408A (ja) * 2009-02-24 2012-08-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAGUCHI MASARU ET AL, BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 126, no. 23, 30 November 2015 (2015-11-30), pages 2390, XP009508502, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
AU2018306329A8 (en) 2025-02-20
WO2019023418A1 (en) 2019-01-31
AU2018306329B2 (en) 2024-09-19
JP7481252B2 (ja) 2024-05-10
CN111432845B (zh) 2024-02-06
KR20200059213A (ko) 2020-05-28
US12251424B2 (en) 2025-03-18
KR102688415B1 (ko) 2024-07-24
CN111432845A (zh) 2020-07-17
JP2020528903A (ja) 2020-10-01
US20200164039A1 (en) 2020-05-28
BR112020001367A2 (pt) 2020-08-11
EP3658191A1 (en) 2020-06-03
AU2018306329A1 (en) 2020-02-13
PH12020500166A1 (en) 2020-09-14
IL272213A (en) 2020-03-31
CA3070442A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
AU2018306329B8 (en) Methods of protecting vascular integrity induced by targeted radiation therapy
Alphandéry Glioblastoma treatments: an account of recent industrial developments
Chanda et al. Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nanoplatform for computer tomography theranostics
Palmowski et al. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions
US20220168392A1 (en) Methods of Enhancing Protection Against Organ and Vascular Injury, Hematopoietic Recovery and Survival in Response to Total Body Radiation/Chemical Exposure
Patenaude et al. Injectable oxygen microparticles boost Radiation–Mediated in situ vaccination and systemic antitumor immune responses
ES2854298T3 (es) Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1
US20070010438A1 (en) Tumor treatment using beta-sheet peptides and radiotherapy
Ashcraft et al. Application of a novel murine ear vein model to evaluate the effects of a vascular radioprotectant on radiation-induced vascular permeability and leukocyte adhesion
JP2025037963A (ja) 放射性微粒子の腫瘍内沈着によるがんの処置方法
HK40033362A (en) Methods of protecting vascular integrity induced by targeted radiation therapy
Johnson et al. VEGF receptor targeted imaging of angiogenic response to limb ischemia in diabetic vs. non-diabetic Yucatan minipigs
US7608612B2 (en) Radiosensitizer formulations and methods for use
US20250312417A1 (en) Methods for Mitigating Lung Injury in Conjunction with Exposure to Radiation and/or Radiation or Radiomimetic Treatments
Zhou et al. Attention to normal brain volumes in glioblastoma radiotherapy: Potential role in tumor invasion and vasculogenesis
EP0692259A2 (en) Use of HCG-specific antibody for the treatment of brain neoplasms
Gan et al. A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
Jensen et al. Clinical Update: treatment of glioblastoma multiforme with radiolabeled antibodies that target tumor necrosis
US9440914B2 (en) Method for treating glioblastomas and other tumors
Nicholson et al. 576: Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach
Werahera et al. 575: Proliferative Tumor Doubling Times of Prostatic Carcinoma Measured by in Vivo Bromodeoxyuridine (BRDU) Labeling and Flow Cytometric Analysis
Miyagi et al. 574: Cellular Interaction Between Prostate Cancer and Bone Stroma: Effects of Radiation on the Growth and Colonization of Human Prostate Cancer Cells in Bone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 58 , NO 37 , PAGE(S) 5419 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME JANSSEN PHARMACEUTICA NV, APPLICATION NO. 2018306329, UNDER INID (72) ADD CO-INVENTOR EICHENBAUM, GARY

Free format text: IN VOL 34 , NO 6 , PAGE(S) 941 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME JANSSEN PHARMACEUTICA NV, APPLICATION NO. 2018306329, UNDER INID (72) ADD CO-INVENTOR EICHENBAUM, GARY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired